CDK4/6 inhibition (CDK4/6i) is effective in the real-world setting for hormone receptor-positive metastatic breast cancer (HR plus MBC) with ESR1 mutations and fusionsJamie O. Brett,Caroline M. Weipert,Lauren L. Ritterhouse,Nicole Zhang, Junhua Yu,Lianne Y. Ryan,Laura M. Spring, Miguel N. Rivera, Jochen K. Lennerz,Dora Dias-Santagata,Leif W. Ellisen,Aditya Bardia, Seth A. WanderCANCER RESEARCH（2022）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
